Acumen Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Acumen Pharmaceuticals, Inc. (ABOS) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$71.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $620.00K.
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$691.00K.
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$157.00K.
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $509.00K, a 39.83% decline year-over-year.
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.36M, a 137.25% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $3.66M, a 890.79% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $369.00K.
- Acumen Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$1.70M, a 143.80% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $620.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$71.00K 10-Q · filed 2026-08-12 | -$228.00K derived: sum of 3 quarters · filed 2026-08-12 | $281.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$691.00K 10-Q · filed 2026-05-12 | -$848.00K derived: sum of 2 quarters · filed 2026-05-12 | -$339.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.10M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $352.00K derived: sum of 2 quarters · filed 2026-03-26 | -$412.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.36M 10-K · filed 2026-03-26 |
| 2025-09-30 | $509.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$255.00K derived: sum of 2 quarters · filed 2026-08-12 | -$1.21M 10-Q · filed 2025-11-12 | -$1.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$764.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.71M 10-Q · filed 2026-08-12 | -$2.25M derived: sum of 3 quarters · filed 2026-08-12 | -$1.41M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$950.00K 10-Q · filed 2026-05-12 | -$1.49M derived: sum of 2 quarters · filed 2026-05-12 | -$644.00K derived: sum of 3 quarters · filed 2026-05-12 | $2.48M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$540.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $306.00K derived: sum of 2 quarters · filed 2026-03-26 | $3.43M derived: sum of 3 quarters · filed 2026-03-26 | $3.66M 10-K · filed 2026-03-26 |
| 2024-09-30 | $846.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.97M derived: sum of 2 quarters · filed 2025-11-12 | $4.20M 10-Q · filed 2025-11-12 | $4.13M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $3.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.35M 10-Q · filed 2025-08-12 | $3.28M derived: sum of 3 quarters · filed 2025-08-12 | $1.79M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $226.00K 10-Q · filed 2025-05-13 | $159.00K derived: sum of 2 quarters · filed 2025-05-13 | -$1.34M derived: sum of 3 quarters · filed 2025-05-13 | -$304.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.56M derived: sum of 2 quarters · filed 2025-03-27 | -$530.00K derived: sum of 3 quarters · filed 2025-03-27 | $369.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$463.00K derived: sum of 2 quarters · filed 2024-11-12 | $436.00K 10-Q · filed 2024-11-12 | $794.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.93M 10-Q · filed 2024-08-13 | $2.29M derived: sum of 3 quarters · filed 2024-08-13 | $3.52M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $899.00K 10-Q · filed 2024-05-14 | $1.26M derived: sum of 2 quarters · filed 2024-05-14 | $2.48M derived: sum of 3 quarters · filed 2024-05-14 | $615.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $1.58M derived: sum of 2 quarters · filed 2024-03-26 | -$284.00K derived: sum of 3 quarters · filed 2024-03-26 | -$1.70M 10-K · filed 2024-03-26 |
| 2022-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$642.00K derived: sum of 2 quarters · filed 2023-11-13 | -$2.06M 10-Q · filed 2023-11-13 | -$2.47M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.28M 10-Q · filed 2023-08-08 | -$3.70M derived: sum of 3 quarters · filed 2023-08-08 | -$509.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.42M 10-Q · filed 2023-05-09 | -$1.83M derived: sum of 2 quarters · filed 2023-05-09 | $1.36M derived: sum of 3 quarters · filed 2023-05-09 | $2.42M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $2.77M derived: sum of 2 quarters · filed 2023-03-27 | $3.84M derived: sum of 3 quarters · filed 2023-03-27 | $3.88M 10-K · filed 2023-03-27 |
| 2021-09-30 | $3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.25M derived: sum of 2 quarters · filed 2022-11-14 | $4.30M 10-Q · filed 2022-11-14 | $4.71M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.11M 10-Q · filed 2022-08-15 | $1.52M derived: sum of 3 quarters · filed 2022-08-15 | $1.46M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $44.00K 10-Q · filed 2022-05-16 | $452.00K derived: sum of 2 quarters · filed 2022-05-16 | $397.00K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $353.00K derived: sum of 2 quarters · filed 2022-03-28 | -$53.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$461.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$406.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |